Resistance to macrolides in Gram-positive bacteria: Clinical impact;Actualité des résistances aux macrolides chez les bactéries à Gram-positif: Impact clinique

Antibiotiques

Volumn 4, Issue 2 I, 2002, Pages 114-121

  Malbruny, B ^a   Leclercq, R ^a  

^a CHU CÔTE DE NACRE   (France)

Author keywords

rythromycin; Efflux; Macrolide; Methylation; Mutation; Resistance; Staphylococcus; Streptococcus

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; KETOLIDE; LINCOSAMIDE DERIVATIVE; MACROLIDE; METHYLTRANSFERASE; METICILLIN; MIDECAMYCIN; MIKAMYCIN B; PENICILLIN G; ROXITHROMYCIN; SPIRAMYCIN; TYLOSIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE; GRAM POSITIVE BACTERIUM; NONHUMAN; PHENOTYPE; RIBOSOME; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0344739582     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Chabbert Y. Antagonisme in vitro entre l'érythromycine et la spiramycine. Ann Inst Pasteur (Paris) 1956 ; 90 : 787-90.
2. Geslin P, Buu-Hoi AY, Fremaux A et al. Antimicrobial resistance in Streptococcus pneumoniae : an epidemiological survey in France, 1970-1980. Clin Infect Dis 1992 ; 15 : 95-8.
3. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect 2000 ; 6 : 661-9.
4. Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides. Drugs 1996 ; 51 : 20-30.
5. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998 ; 27 : S32-S41.
6. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995 ; 39 : 577-85.
7. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991 ; 35 : 1267-72.
8. Roberts MC, Sutcliffe J, Courvalin P et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999 ; 43 : 2823-30.
9. Rosato A, Vicarini H, Bonnefoy A et al. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob Agents Chemother 1998 ; 42 : 1392-6.
10. Lina G, Quaglia A, Reverdy ME et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999 ; 43 : 1062-6.
11. Leclercq R, Bauduret F, Soussy CJ. Selection of constitutive mutants of Gram-positive cocci inducible resistant to macrolides, lincosamides and streptogramins (MLS) : comparison of the selective effects of the MLS. Pathol Biol (Paris) 1989 ; 37 : 568-72.
12. Angot P, Vergnaud M, Auzou M et al. Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Observatoire de Normandie du Pneumocoque. Eur J Clin Microbiol Infect Dis 2000 ; 19 : 755-8.
13. Fitoussi F, Doit C, Geslin P et al. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob Agents Chemother 2001 ; 45 : 636-8.
14. Syrogiannopoulos GA, Grivea IN, Tait-Kamradt A et al. Identification of an erm(A) erythromycin resistance methylase gene in Streptococcus pneumoniae isolated in Greece. Antimicrob Agents Chemother 2001 ; 45 : 342-4.
15. Bingen E, Fitoussi F, Doit C et al. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob Agents Chemother 2000 ; 44 : 1453-7.
16. Rosato A, Vicarini H, Leclercq R. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J Antimicrob Chemother 1999 ; 43 : 559-62.
17. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother 2001 ; 45 : 1-12.
18. Stamm LV, Bergen HL. A point mutation associated with bacterial macrolide resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate. Antimicrob Agents Chemother 2000 ; 44 : 806-7.
19. Ross JI, Eady EA, Cove JH et al. Resistance to erythromycin and clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA. Dermatology 1998 ; 196 : 69-70.
20. Tait-Kamradt A, Davies T, Appelbaum PC et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000 ; 44 : 3395-401.
21. Tait-Kamradt A, Davies T, Cronan M et al. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000 ; 44 : 2118-25.
22. Coffey TJ, Dowson CG, Daniels M et al. Genetics and molecular biology of betalactam-resistant pneumococci. Microb Drug Resist 1995 ; 1 : 29-34.
23. Varon E, Gutmann L. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae. Res Microbiol 2000 ; 151 : 471-3.
24. Ross JI, Eady EA, Cove JH et al. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mol Microbiol 1990 ; 4 : 1207-14.
25. Schmitz FJ, Sadurski R, Kray A et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000 ; 45 : 891-4.
26. Arpin C, Daube H, Tessier F et al. Presence of mefA and mefE genes in Streptococcus agalactiae. Antimicrob Agents Chemother 1999 ; 43 : 944-6.
27. Kataja J, Seppala H, Skurnik M et al. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob Agents Chemother 1998 ; 42 : 1493-4.
28. Clancy J, Petitpas J, Dib-Hajj F et al. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mol Microbiol 1996 ; 22 : 867-79.
29. Tait-Kamradt A, Clancy J, Cronan M et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997 ; 41 : 2251-5.
30. Santagati M, Iannelli F, Oggioni MR et al. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000 ; 44 : 2585-7.
31. Fitoussi F, Doit C, Geslin P et al. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrab Agents Chemother 2001 ; 45 : 636-8.
32. Fitoussi F, Loukil C, Gros I et al. Mechanisms of macrolide resistance in clinical group B streptococci isolated in France. Antimicrob Agents Chemother 2001 ; 45 : 1889-91.
33. Arthur M, Andremont A, Courvalin P. Distribution of erythromycin esterase and rRNA methylase genes in members of the family Enterobacteriaceae highly resistant to erythromycin. Antimicrob Agents Chemother 1987 ; 31 : 404-9.
34. Nakamura A, Nakazawa K, Miyakozawa I et al. Macrolide esterase-producing Escherichia coli clinically isolated in Japan. J Antibiot (Tokyo) 2000 ; 53 : 516-24.
35. Matsuoka M, Endou K, Kobayashi H et al. A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus. FEMS Microbiol Lett 1998 ; 167 : 221-7.
36. Yazawa K, Mikami Y, Sakamoto T et al. Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species. Antimicrob Agents Chemother 1994 ; 38 : 2197-9.
37. Amsden GW. Pneumococcal macrolide resistance : myth or reality? J Antimicrob Chemother 1999 ; 44 : 1-6.
38. Dagan R, Klugman KP, Craig WA et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001 ; 47 : 129-40.
39. Dagan R, Leibovitz E, Greenberg D et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998 ; 17 : 776-82.
40. Dagan R, Leibovitz E, Fliss DM et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000 ; 44 : 43-50.
41. Kelley MA, Weber DJ, Gilligan P et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000 ; 31 : 1008-11.
42. Varaldo PE, Debbia EA, Nicoletti G et al. Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children : influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy Study Group. Clin Infect Dis 1999 ; 29 : 869-73.